You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Nearly 500 mn doses of Covid-19 vaccine by July 2021, says Harsh Vardhan

He also said that the government was also keeping an eye on immunity data with regard to Covid-19 while finalising these plans

Topics
Coronavirus Vaccine | Coronavirus | Harsh Vardhan

Ruchika Chitravanshi  |  New Delhi 

covid, coronavirus, vaccine, drug, pharma
The committee led by V K Paul, member - health, NITI Aayog is drawing up the plan for the entire process of vaccine procurement and distribution.

India is planning to use 400-500 million doses to vaccinate around 250 million people by July 2021 for the infection, Health Minister said on Sunday, while laying out the broad outlines of the country’s vaccine strategy.

States have been asked to submit the lists of populations that will be first in line to receive the vaccination, such as frontline health workers and those with underlying health conditions, by October-end. The government has also started the exercise of getting a lowdown on the status of vaccine development. The Centre, said Vardhan, is seeking commitments from vaccine makers to make the maximum number of doses available for India’s inventory and supply chain management. “The government is committed to taking all measures to ensure equitable access to vaccines,” he said.

Three vaccine candidates are the frontrunners in India: Zydus Cadila, Bharat Biotech and Serum Institute for the Oxford-AstraZeneca vaccine. Phase two human clinical trials for Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D and phase three trials for Oxford-AstraZeneca’s Covishield are underway.

The government has not taken any decision on the clinical trials of Russia’s Sputnik V vaccine yet, Vardhan said.

Besides the vaccines, the government is also taking stock of the cold chain facilities and related infrastructure down to the block level across states, which will be required for vaccine distribution.

ALSO READ: Trump's Covid-19 condition improving, could return to WH on Monday: Doctors

Industry experts believe India has a fairly developed cold chain network, especially due to an extensive national programme.

India has used the Electronic Vaccine Intelligence Network (eVIN) to track information on vaccine supply chain and stocks across the country during the Covid-19 pandemic. This was done to ensure smooth across the country. This system provides real-time information on stocks and temperatures across registered vaccine storage sites in India. The network has 23,900 digital temperature loggers and 41,420 cold chain handlers for digital record-keeping.

Vardhan said the government is also working on ramping up human resource and training capacity on a massive scale.


chart

The committee led by V K Paul, member-health, Niti Aayog, is drawing up the plan for the process of vaccine procurement and distribution. “Vaccine procurement is being done centrally and each consignment will be tracked real-time until delivery to ensure it reaches those who need it most,” the minister said.

The government is hoping to have its ducks in a row by the time the vaccines are ready to ensure swift roll-out of the programme.

Vardhan also said that vaccines will be distributed according to pre-decided priority and in a programmed manner. “To ensure transparency and accountability, details of the entire process will be shared in the coming months.”

The data around immunity already achieved against Covid-19 in the country will be taken into account while finalising the vaccine-related plans. However, the government has not yet shared the total cost of vaccination and ways of financing it.

On September 26, Serum Institute’s chairman Adar Poonawalla tweeted: “Will the government of India have Rs 80,000 crore available, over the next one year? Because that’s what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India. This is the next concerning challenge we need to tackle.”

India’s vaccine making abilities are among the highest in the world and the government has said in the past that even if any other country succeeds in developing a vaccine before us, either India or China will ultimately have to scale it up.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, October 04 2020. 15:51 IST
RECOMMENDED FOR YOU